ArticleDisease models & mechanisms2026
Mesoscale maladaptation in disease organoids.
Article in Disease models & mechanisms, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Enhancing the in vitro architecture of human disease.Disease models & mechanisms · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
In chronic diseases, multiple tissue components at a shared interface often deteriorate concurrently, and disease progression may depend on interactions among these failures rather than on any single defect. Multi-tissue organoid models can mimic disease-relevant pathology in vitro, but the field lacks a simple framework for comprehensive interrogation. Here, we propose mesoscale maladaptation as an operational concept for multi-tissue disease modelling, defined as a synergistic decline in interdependent functions that can occur between two or more tissue elements. To detect maladaptation, we introduce a stepwise workflow that identifies the failing tissue elements, defines directionality of potential interdependence between these elements and compares combined perturbations with single perturbations to evaluate synergistic decline. We apply this framework to intestinal neuromuscular, hepatic sinusoidal, blood-brain barrier and tumour-neural interfaces, but it can be extrapolated to other organs and systems. This framework will illuminate future directions for in vitro complex disease modelling by enriching biological insights to disentangle progressive pathology, shifting the focus from localised biological failures to concurrent multi-tissue failures that produce synergistic pathology.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.